Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bromazepam** is a benzodiazepine medication primarily used for the short-term treatment of severe anxiety and panic disorders. It acts as a positive allosteric modulator at the GABA-A receptor, enhancing the inhibitory effect of gamma aminobutyric acid (GABA) in the central nervous system, which produces anxiolytic, sedative, hypnotic, and muscle relaxant effects[1][2][5]. It does not possess antidepressant or antipsychotic properties. Developed as part of the classical benzodiazepine class, it has an intermediate onset and duration of action. The drug carries risks typical to benzodiazepines including dependence, withdrawal symptoms with abrupt cessation, and potential for misuse or abuse[2][5]. It is approved in many countries but not in the United States[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromazepam.